Proton pump inhibitors (PPI) are one of the most commonly used prescription drugs in the world, with a use rate of 11-30%among all adults. However, due to its potential carcinogenic effects and other major health complications, the security of PPI for a long time has become increasingly questioned.
Previous studies have shown that PPI can change the richness and diversity of intestinal microbial groups. According to preclinical research, the intestinal ecological disorders caused by it may lead to the development of colorectal cancer (CRC). Therefore, the research aims to evaluate the correlation between the use of PPI and the specific mortality of CRC.
Researchers collected all patients who were diagnosed with CRCs (N = 32, 411, 54.9%PPI users) registered at the Swedish prescription drug registration office from 2006 to 2012, and then tracked patients through the registration link of the Swedish death registration office. Until December 2013.
The results showed that a total of 4,746 (14.0%) patients died, and the AHR (risk ratio after adjustment) of PPI users and PPI non -users was 1.38. Observe a higher associated type in men, cancer 0- I, rectal cancer, and patients with CRC surgery.
Comparison between new users and non -users (AHR = 1.47) between new users and non -user (AHR = 1.32) between new users and non -user (AHR = 1.47) is more significant. The risk estimation value of the CRC specific mortality of PPI users and PPI non -users is similar to the patient’s risk estimation value of the patient’s mortality rate.
All in all, the results of the study revealed that the use of PPI after diagnosis of CRC is related to the increase in the patient’s mortality and CRC specific mortality.
Wang, X., LIU, Q., Halfdanarson, ó.?. Et Al. Proton pump inhibitors and Survival in Patients with Colorectal Cancer: A Swedish Popuration-Based Cohort STUDY (12 JULY 2 JULYER.